(Q37390143)

20 August 2017

1 reference

title

The potential role and application of PARP inhibitors in cancer treatment (English)

1 reference

20 August 2017

Anthony J Chalmers

1

1 reference

20 August 2017

publication date

9 February 2009

1 reference

20 August 2017

published in

British Medical Bulletin

1 reference

20 August 2017

volume

89

1 reference

20 August 2017

page(s)

23-40

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

20 August 2017

1 reference

A concise review of DNA damage checkpoints and repair in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Cell-cycle checkpoints and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

DNA repair deficiency as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

The role of poly(ADP-ribose) in the DNA damage signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Poly(ADP-ribose)polymerase inhibition - where now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

The role of double-strand break repair — insights from human genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Benzamide protects delayed neuronal death and behavioural impairment in a mouse model of global cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Chemopotentiation by PARP inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDP005

21 January 2018

Identifiers

DOI

10.1093/BMB/LDP005

1 reference

20 August 2017

1 reference